Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
02/2003
02/06/2003WO2002067851A3 Method for treating fibrotic diseases or other indications iiic
02/06/2003WO2002064586A3 Heterocyclic inhibitors of erk2 and uses thereof
02/06/2003WO2002063005A3 Lipid-associated molecules
02/06/2003WO2002061110A3 Nucleic acid derivatives
02/06/2003WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors
02/06/2003WO2002048134A3 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
02/06/2003WO2002041843A3 Antiinflammation agents
02/06/2003WO2002030937A3 Labeled resiniferatoxin derivatives for use in vanilloid receptor binding assay
02/06/2003WO2002028904A3 Human anti-cd40 antibodies
02/06/2003WO2002020722A3 Methods and compositions for in vitro targeting
02/06/2003WO2002019963A3 Synthetic erythropoiesis stimulating proteins
02/06/2003WO2002010217A9 Endothelial cell expression patterns
02/06/2003WO2002010137A9 Indazole derivatives as jnk inhibitors
02/06/2003WO2002002095A3 Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin
02/06/2003US20030028036 Cyclooxygenase-2 (COX-2); preparing 4-(4-alkylsulfonyl-phenyl)-2,5-dihydro-furan-2-ones by reacting 2-alkoxy-2-(4-alkylsulfonylphenyl)oxetane with a substituted carboxylic acid and then cyclizing that product
02/06/2003US20030028028 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels
02/06/2003US20030028021 Chemical compounds
02/06/2003US20030028008 Nucleotide sequences coding polypeptide for use in the treatment of urogenital, tumor, antherosclerotic and kidney disorders
02/06/2003US20030028006 Cytokine receptor common gamma chain like
02/06/2003US20030027999 143 human secreted proteins
02/06/2003US20030027861 6-Methoxy-2-naphthylacetic acid prodrugs
02/06/2003US20030027860 6-Methoxy-2-naphthylacetic acid prodrugs
02/06/2003US20030027852 Substituted pyrrolidine-2,3,4-trione 3-oxime deerivatives which are active as NMDA receptor antagonists
02/06/2003US20030027851 Readily soluble crystal modification; specific X-ray diffraction pattern obtained with a focusing Debye-Scherrer beam and Cu-K alpha 1-radiation
02/06/2003US20030027845 Ether derivatives useful as inhibitors of PDE4 isozymes
02/06/2003US20030027836 Arylalkoxy-substituted tetrahydroisoquinoline-3-carboxylic acids or esters
02/06/2003US20030027820 Method for treating fibrotic diseases or other indications V
02/06/2003US20030027814 Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases
02/06/2003US20030027807 Vitronectin receptor antagonists, their preparation and their use
02/06/2003US20030027806 Triptolide analogs for the treatment of autoimmune and inflammatory disorders
02/06/2003US20030027795 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
02/06/2003US20030027794 N-heterocyclic derivatives as NOS inhibitors
02/06/2003US20030027783 Introducing into the cell an RNA comprising a double stranded structure having nucleotide sequence which is substantially identical to part of target gene and which is derived from an endogenous template; verifying inhibition of expression
02/06/2003US20030027764 Novel therapeutic and prophylactic agents and methods of using same
02/06/2003US20030027752 Leucine-based motif and clostridial neurotoxins
02/06/2003US20030027744 Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye
02/06/2003US20030027284 Tumor necrosis factor-gamma
02/06/2003US20030027261 Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof
02/06/2003US20030027253 Nucleotides equences codin polypeptide for use in the treatment of cancer
02/06/2003US20030027232 Novel compounds
02/06/2003US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides
02/06/2003US20030026862 (+)-Cycloolivil as antioxidant obtained from a new natural source namely stereospermum personatum
02/06/2003US20030026805 Genetic engineering; monoclonal antibody grafted to tumor necrosis factor
02/06/2003US20030026796 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
02/06/2003CA2857312A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using deoxyhypusine synthase (dhs)
02/06/2003CA2455602A1 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
02/06/2003CA2454822A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using apoptosis-specific eif-5a
02/06/2003CA2454805A1 Probiotic lactobacillus casei strains
02/06/2003CA2454803A1 Probiotic bifidobacterium strains
02/06/2003CA2454562A1 Method of improving cognitive function
02/06/2003CA2454342A1 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
02/06/2003CA2454150A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same
02/06/2003CA2453561A1 Use of the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent
02/06/2003CA2452328A1 Substituted piperidines as modulators of the melanocortin receptor
02/06/2003CA2452259A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
02/06/2003CA2452159A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
02/05/2003WO2002014280A1 Piperidine derivatives and drugs containing these derivatives as the active ingredient
02/05/2003EP1281962A1 Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and an SH3 domain comprising peptide
02/05/2003EP1281756A1 Regulator of calcineurin
02/05/2003EP1281709A1 Novel heterocyclic compounds with anti-inflammatory activity
02/05/2003EP1281404A2 Use of antibodies against the urokinase receptor
02/05/2003EP1281401A2 The medical effect of Jojoba oil
02/05/2003EP1281397A1 Orally administered controlled drug delivery system providing temporal and spatial control
02/05/2003EP1281392A1 Cosmetic or/and pharmaceutical compositions containing plant extracts
02/05/2003EP1281083A1 Methods for detecting inflammation and inflammatory conditions
02/05/2003EP1280904A2 Pain signaling molecules
02/05/2003EP1280897A2 Regulation of nf-at interacting protein nip 45 variant
02/05/2003EP1280891A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
02/05/2003EP1280826A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
02/05/2003EP1280820A2 Anti-inflammatory compounds and uses thereof
02/05/2003EP1280815A1 29 human secreted proteins
02/05/2003EP1280806A1 THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
02/05/2003EP1280802A1 Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
02/05/2003EP1280800A1 N-sulfonyl hydroxamic acid derivatives as inhibitors of cd 23
02/05/2003EP1280799A1 Ortho-substituted anthranilic acid amides and their use as medicaments
02/05/2003EP1280798A1 Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
02/05/2003EP1280797A1 Inhibitors of dipeptidyl peptidase iv
02/05/2003EP1280789A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
02/05/2003EP1280776A1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
02/05/2003EP1280774A1 Substituted indoles as parp inhibitors
02/05/2003EP1280572A1 Delivery devices for treatment of vascular disease
02/05/2003EP1280570A2 Delivery devices for treatment of vascular disease
02/05/2003EP1280569A1 Delivery systems for treatment of vascular disease
02/05/2003EP1280568A1 Delivery devices for treatment of vascular disease
02/05/2003EP1280547A2 Mast cell regulation
02/05/2003EP1280546A1 Method and composition for the treatment of angiogenesis
02/05/2003EP1280544A1 Hyaluronidase activity and allergenic cell activity inhibitor
02/05/2003EP1280537A2 Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof
02/05/2003EP1280536A2 Method for treating retinal degeneration with purinergic receptor agonists
02/05/2003EP1280529A2 Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
02/05/2003EP1280525A2 Methods and compositions for modulating alpha adrenergic receptor activity
02/05/2003EP1280524A2 Methods and compositions for modulating alpha adrenergic receptor activity
02/05/2003EP1280518A2 Liposome drug delivery
02/05/2003EP1280515A2 Pharmaceutical compositions comprising cannabis
02/05/2003EP1280512A2 Delivery systems for treatment of vascular disease
02/05/2003EP1280416A1 Pet food composition for reducing inflammatory response in cats
02/05/2003EP1117653B1 Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
02/05/2003EP1037868B1 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
02/05/2003EP1003486B1 Pharmaceutical compositions containing an effervescent acid-base couple
02/05/2003EP0848706B1 Substituted benzene-fused heterocyclics as neurokinin antagonists
1 ... 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 ... 1272